At CustoScan, we provide Cell and Gene Therapy (CGT) related diagnostic antibodies and upstream manufacturing materials.
CAR T-cell Therapy detection antibodies, e.g., anti-CD19 or BCMA CAR T-cell Therapy detection antibodies, are created by antibody specialist BioSwan Laboratories Inc. based in Shanghai, China, for customers in the EU, USA, and APAC. BioSwan's revolutionary anti-CD19 CAR T-cell Therapy detection antibody (Rabbit Anti-Mouse FMC63 scFv) enables an industry-leading detection of 1 CD19 CAR T-cell in 100,000 PBMCs from a patient sample in a flow cytometric assay (i.e., 0.001% of limit detection).
They feature the highest sensitivity for CAR T-Cell detection currently available.With their superior accuracy, precision, and sensitivity, they are pushing the envelope of CAR T-Therapy. Besides the ready industrial CART antibodies, customized antibody production based on the proprietary in-house antibody development platform by BioSwan Laboratories Inc. is also available.
BioSwan's detection antibodies are used by multinational companies, life science start-ups, and even Harvard University in the US.
CGT related Recombinant Proteins for the upstream core CGT manufacturing are created by T&L Biotechnology LTD from Beijing, China.
Their products include eukaryotic recombinant proteins, cytokines, and drug target antigens.
The company has built advanced class 10,000 clean room manufacturing facilities with cGMP standards, including a mammalian cell expression recombinant protein engineering platform, in vitro diagnostic reagent production platform, and a cell therapy development platform. T&L are dual ISO13485 and ISO9001 certified, hold a NK cell manufacturing patent, and a number of their products have been registered with the FDA and DMF.